New pages

2 July 2026

• 13:2513:25, 2 July 2026 SEPHIENCE-Sepiapterin powder (hist | edit) [27,384 bytes] Anum Ijaz (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{AIJ}} |aOrAn=a |drugClass=phenylalanine hydroxylase (PAH) activator |indicationType=treatment |indication=hyperphenylalaninemia (HPA) in adult and pediatric patients 1 month of age and older with sepiapterin-responsive phenylketonuria (PKU). SEPHIENCE is to be used in conjunction with a phenylalanine (Phe)- restricted diet. |adverseReactions=diarrhea, headache, abdominal pain, hypophenylalaninemia,...") originally created as "Sepiapterin powder"

28 June 2026

• 22:1522:15, 28 June 2026 ANZUPGO - Delgocitinib cream (hist | edit) [23,079 bytes] Anum Ijaz (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{AIJ}} |aOrAn=a |drugClass=Janus kinase (JAK) inhibitor |indicationType=treatment |indication=moderate to severe chronic hand eczema (CHE) in adults who have had an inadequate response to, or for whom topical corticosteroids are not advisable. |adverseReactions=application site pain, paresthesia, pruritus, erythema, and bacterial skin infections including finger cellulitis, paronychia, ot...") originally created as "Delgocitinib"

26 June 2026

• 10:0010:00, 26 June 2026 Cardiac resynchronization therapy device management (hist | edit) [18,642 bytes] Nehal Eid (talk | contribs) (Created page with "```wikitext __NOTOC__ ==Device management== Post-implantation management of cardiac resynchronization therapy (CRT) focuses on maintaining effective resynchronization, detecting device- and heart-failure–related deterioration, managing apparent non-response, and planning generator replacement, imaging, infection care, and goals-of-care discussions. Initial implantation technique, primary CRT indications, and primary conduction-system pacing strategies are address...")

24 June 2026

• 00:5000:50, 24 June 2026 Summary and evolution of AIS Guidelines (hist | edit) [21,092 bytes] Hasnain Ali (talk | contribs) (Created page with "__NOTOC__ {{Ischemic stroke}} {{CMG}}{{AE}} {{HAM}} ==Summary Evolution of AHA/ASA Stroke Guidelines: 2018<ref name="pmid29367334">{{cite journal| author=Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K | display-authors=etal| title=2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. | journal=Stroke | year= 201...")

23 June 2026

• 23:3123:31, 23 June 2026 Sandbox:HAM (hist | edit) [91,907 bytes] Hasnain Ali (talk | contribs) (Created page with "== 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association == === DIAGNOSTIC EVALUATION FOR SECONDARY STROKE PREVENTION === {| class="wikitable" style="width:80%" |- | colspan="1" style="text-align:center; background:LightGreen" |Class I |- | bgcolor="LightGreen" |'''1.'...")

16 June 2026

• 14:3214:32, 16 June 2026 EKTERLY - Sebetralstat tablet (hist | edit) [23,436 bytes] Anum Ijaz (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{AIJ}} |aOrAn=a |drugClass=plasma kallikrein inhibitor |indicationType=treatment |indication=acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older. |adverseReactions=headache(incidence ≥2%). |blackBoxWarningTitle='''<span style="color:#FF0000;">TITLE</span>''' |blackBoxWarningBody=''<span style="color:#FF0000;">Condition Name:</span>'' (Content) |fdaLIADAdult=====FDA-labeled Indi...") originally created as "Sebetralstat"